DEFIROX 125 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

DEFERASIROX

متاح من:

DEXCEL LTD, ISRAEL

ATC رمز:

V03AC03

الشكل الصيدلاني:

DISPERSIBLE TABLETS

تركيب:

DEFERASIROX 125 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

PHARMASCIENCE INC., CANADA

المجال العلاجي:

DEFERASIROX

الخصائص العلاجية:

Defirox is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). Defirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 µg/l). LIC is the preferred method of iron overload determination and should be used wherever available

تاريخ الترخيص:

2021-07-22